Published in Vaccine Weekly, January 7th, 2004
This special accommodation will apply to those individuals for whom FluMist is recommended by the Centers for Disease Control and Prevention (CDC). The CDC, following indications approved by the U.S. Food and Drug Administration, has recommended the use of FluMist for healthy children and adults between the ages of 5 and 49.
G. Fred DiBona, Jr., AmeriHealth chairman, President and chief executive officer, said the company hoped the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.